M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Magnetic Resonance Elastography and 2-Point Dixon MR Imaging Techniques in Diffuse Liver Disease

Phase 1

Completed

Conditions: Liver Cancer

Interventions: Diagnostic Test: Magnetic Resonance Elastogram
Diagnostic Test: 2-Point Dixon Magnetic Resonance Imaging

First Posted Date: 2007-10-15

Last Posted Date: 2021-04-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 44

Registration Number: NCT00543777

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer

Phase 1

Terminated

Conditions: Lung Cancer

Interventions: Drug: Sorafenib
Procedure: Radiation Therapy

First Posted Date: 2007-10-12

Last Posted Date: 2018-11-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 10

Registration Number: NCT00543335

Locations: 🇺🇸
UT MD . Anderson Cancer Center, Houston, Texas, United States

The Exceptional Patient in Cancer Care

Completed

Conditions: Advanced Cancer

Interventions: Behavioral: Interview

First Posted Date: 2007-10-12

Last Posted Date: 2012-07-30

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 13

Registration Number: NCT00543153

Locations: 🇮🇱
Tel Aviv University, Tel Aviv, Israel
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006)

Phase 1

Completed

Conditions: Acute Myeloid Leukemia
AML
Myelodysplastic Disorders

Interventions: Drug: Idarubicin
Drug: Sorafenib
Drug: Ara-C

First Posted Date: 2007-10-12

Last Posted Date: 2018-08-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 78

Registration Number: NCT00542971

Locations: 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States

Evaluate the Use of Paravertebral Block in Reconstructive Breast Surgery

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Procedure: Paravertebral Block
Drug: Propofol
Drug: Ropivacaine
Drug: Fentanyl
Drug: Midazolam

First Posted Date: 2007-10-11

Last Posted Date: 2015-04-13

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 89

Registration Number: NCT00542542

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Widefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer

Not Applicable

Active, not recruiting

Conditions: Tobacco Use Disorder
Fanconi Anemia
Premalignant Lesion
Oral Cavity and Lip Precancerous Condition
Erythroplakia
Lichen Planus
Oral Cavity Leukoplakia
Oral Neoplasm

Interventions: Other: Cytology Specimen Collection Procedure
Procedure: Diagnostic Microscopy
Procedure: Diagnostic Procedure
Procedure: Fluorescence Imaging
Procedure: Fluorescence Spectroscopy

First Posted Date: 2007-10-11

Last Posted Date: 2024-10-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 338

Registration Number: NCT00542373

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Home-Based Measures of Physical Activity and Body Composition

Not Applicable

Active, not recruiting

Conditions: Cardiovascular Disease

Interventions: Behavioral: Environmental Assessments
Behavioral: Physical Activity Recall

First Posted Date: 2007-10-11

Last Posted Date: 2025-01-10

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 62

Registration Number: NCT00542438

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma

Withdrawn

Conditions: Mantle Cell Lymphoma
Lymphoma

Interventions: Procedure: PET/CT Scanning

First Posted Date: 2007-10-10

Last Posted Date: 2012-12-06

Lead Sponsor: M.D. Anderson Cancer Center

Registration Number: NCT00541424

Autologous Stem Cell Rescue With CD133+ Selected Cells in High-Risk Neuroblastoma

Phase 2

Terminated

Conditions: Neuroblastoma

Interventions: Drug: Carboplatin
Drug: Etoposide
Drug: Melphalan
Procedure: Stem Cell Infusion
Device: ClinicMACS

First Posted Date: 2007-10-04

Last Posted Date: 2019-07-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT00539500

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

A Pilot Study to Evaluate Nipple-Areolar Complex (NAC) Sparing Mastectomy

Completed

Conditions: Breast Cancer

Interventions: Procedure: NAC Sparing Mastectomy
Behavioral: Questionnaire

First Posted Date: 2007-10-04

Last Posted Date: 2013-08-26

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 37

Registration Number: NCT00539227

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy